Verrica Pharmaceuticals (STU:1NE0) Short Percentage of Float


STU:1NE0 Verrica Pharmaceuticals Inc STU:1NE0
45 GF Score
Price €5.31
GF Value €12.59
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Verrica Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:1NE0 vs ENGN, PEPG, ONCY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Verrica Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verrica Pharmaceuticals Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Verrica Pharmaceuticals's Short Percentage of Float falls into.


STU:1NE0
45GF Score
Verrica Pharmaceuticals Inc STU:1NE0
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Verrica Pharmaceuticals (STU:1NE0) Overvalued in 2026?

Based on GuruFocus' analysis, Verrica Pharmaceuticals stock appears to be undervalued. The current stock price of €5.31 is trading 57.8% below its estimated GF Value™ of €12.59. GuruFocus considers Verrica Pharmaceuticals to be Possible Value Trap.

Key valuation signals for STU:1NE0:

  • Short Percentage of Float:
  • GF Value™: €12.59 vs. price of €5.31 (57.8% below fair value)
  • GF Score™: 45/100 with 2 warning signs

No single metric tells the full story. See the STU:1NE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Verrica Pharmaceuticals Business Description

Other Exchanges VRCA:USA1NE0:Germany
Address 44 West Gay Street, Suite 400, West Chester, PA, USA, 19380
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
45GF Score

Get the complete analysis for STU:1NE0

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.31
Price
€12.59
GF Value